BioAdvance

BioAdvance is a $50M early stage life sciences fund, working with entrepreneurs in the mid-Atlantic region to build strong companies that have the potential to improve human health. Since making its first investments in 2003, BioAdvance has committed $39.24M in funding to 87 organizations developing over 85 products in the diagnostics, therapeutic, medtech, research tools and digital health sectors. BioAdvance portfolio companies have leveraged $2.67 billion in subsequent capital, including proceeds from twelve acquisitions. Eleven products have received FDA approval. Learn more